Elevation of ISG15 promotes diabetic kidney disease by modulating renal tubular epithelial cell pyroptosis

Abstract

Background: Fibrosis and inflammation in the renal tubular epithelial cells (TECs) are key contributors to the pathology of diabetic kidney disease (DKD). Nevertheless, the precise triggers of these processes remain unclear. This study aimed to explore the role of interferon-stimulated gene 15 (ISG15) in the injury of TECs induced by high glucose (HG) conditions and its implications for the development of DKD.

Methods: ISG15 knockout (ISG15 KO) mice injected with streptozotocin-treated mice on a high-fat diet were used to investigate its role in DKD. Cellular models with ISG15 knockdown were exposed to HG conditions to assess the effects of ISG15 on cellular responses. Subsequently, we evaluated the impact of ISG15 on pyroptosis, a form of programmed cell death, to understand its potential role in DKD pathology. Furthermore, RNA sequencing (RNA-seq) and molecular biology techniques were employed to explore the signalling pathways potentially regulated by ISG15.

Results: We first confirmed an up-regulation of ISG15 within the renal tubule in DKD. The deletion of ISG15 alleviated renal functional damage, fibrosis and inflammation, which correlated with reduced ISGylation levels. Mechanistic investigation revealed that HG stimulation in TECs disrupted the mtDNA–cGAS–STING signalling, which exacerbates the DKD through the NLRP3–CASP1–GSDMD axis. Furthermore, we uncovered a bidirectional regulatory loop between STING and ISG15, with STING enhancing ISG15 expression upstream and ISG15 modulating STING expression through ISGylation.

Conclusion: ISG15–mtDNA–STING emerges as a critical hub that integrates the processes of pyroptosis, fibrosis and inflammation. Therapeutic interventions that target this signalling network at various levels may pave the way for innovative treatments for DKD.

Keywords

diabetic kidney disease / fibrosis / ISG15 / pyroptosis / renal tubular epithelial cells

References

[1] Mohandes S, Doke T, Hu H, Mukhi D, Dhillon P, Susztak K. Molecular pathways that drive diabetic kidney disease. The Journal of Clinical Investigation. 2023; 133(4): 1-12.

[2] Xu C, Ha X, Yang S, Tian X, Jiang H. Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms. Front Endocrinol (Lausanne). 2023; 14: 1232790.

[3] Hu Q, Chen Y, Deng X, et al. Diabetic nephropathy: focusing on pathological signals, clinical treatment, and dietary regulation. Biomed Pharmacother. 2023; 159: 114252.

[4] Xu F, Jiang H, Li X, et al. Discovery of prdm16-mediated trpa1 induction as the mechanism for low tubulo-interstitial fibrosis in diabetic kidney disease. Adv Sci (Weinh). 2024; 11(7): e2306704.

[5] Dikun KM, Tang XH, Fu L, Choi ME, Lu C, Gudas LJ. Retinoic acid receptor alpha activity in proximal tubules prevents kidney injury and fibrosis. Proc Natl Acad Sci USA. 2024; 121(7): e1983164175.

[6] Yao L, Liang X, Qiao Y, Chen B, Wang P, Liu Z. Mitochondrial dysfunction in diabetic tubulopathy. Metabolism. 2022; 131: 155195.

[7] Cleveland KH, Schnellmann RG. Pharmacological targeting of mitochondria in diabetic kidney disease. Pharmacol Rev. 2023; 75(2): 250-262.

[8] Zhou Y, Liu L, Jin B, et al. Metrnl alleviates lipid accumulation by modulating mitochondrial homeostasis in diabetic nephropathy. Diabetes. 2023; 72(5): 611-626.

[9] Haas AL, Ahrens P, Bright PM, Ankel H. Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. J Biol Chem. 1987; 262(23): 11315-11323.

[10] Loeb KR, Haas AL. The interferon-inducible 15-kda ubiquitin homolog conjugates to intracellular proteins. J Biol Chem. 1992; 267(11): 7806-7813.

[11] Zhang D, Zhang DE. Interferon-stimulated gene 15 and the protein isgylation system. J Interferon Cytokine Res. 2011; 31(1): 119-130.

[12] Schoggins JW. Interferon-stimulated genes: what do they all do?. Annu Rev Virol. 2019; 6(1): 567-584.

[13] Sandy Z, Da CI, Schmidt CK. More than meets the isg15: emerging roles in the dna damage response and beyond. Biomolecules. 2020; 10(11).

[14] Perng YC, Lenschow DJ. Isg15 in antiviral immunity and beyond. Nat Rev Microbiol. 2018; 16(7): 423-439.

[15] Munnur D, Teo Q, Eggermont D, et al. Altered isgylation drives aberrant macrophage-dependent immune responses during SARS-cov-2 infection. Nat Immunol. 2021; 22(11): 1416-1427.

[16] Xu T, Zhu C, Chen J, et al. Isg15 and isgylation modulates cancer stem cell-like characteristics in promoting tumor growth of anaplastic thyroid carcinoma. J Exp Clin Cancer Res. 2023; 42(1): 182.

[17] Cao X. Isg15 secretion exacerbates inflammation in SARS-cov-2 infection. Nat Immunol. 2021; 22(11): 1360-1362.

[18] Sarkar L, Liu G, Gack MU. Isg15: its roles in SARS-cov-2 and other viral infections. Trends Microbiol. 2023; 31(12): 1262-1275.

[19] Meng Y, Bian L, Zhang M, et al. Isg15 promotes progression and gemcitabine resistance of pancreatic cancer cells through atg7. Int J Biol Sci. 2024; 20(4): 1180-1193.

[20] Dai Y, Yu T, Yu C, et al. Isg15 enhances glioma cell stemness by promoting oct4 protein stability. Environ Toxicol. 2022; 37(9): 2133-2142.

[21] Mcewen DP, Ray P, Nancarrow DJ, et al. Isg15/grail1/cd3 axis influences survival of patients with esophageal adenocarcinoma. Jci Insight. 2024; 9(13).

[22] Zhang HF, Liu HM, Xiang JY, et al. Alpha lipoamide inhibits diabetic kidney fibrosis via improving mitochondrial function and regulating rxralpha expression and activation. Acta Pharmacol Sin. 2023; 44(5): 1051-1065.

[23] Hu H, Li W, Hao Y, Peng Z, Zou Z, Liang W. Baicalin ameliorates renal fibrosis by upregulating cpt1alpha-mediated fatty acid oxidation in diabetic kidney disease. Phytomedicine. 2024; 122: 155162.

[24] Wei X, Xie F, Zhou X, et al. Role of pyroptosis in inflammation and cancer. Cell Mol Immunol. 2022; 19(9): 971-992.

[25] Ye S, Zhang M, Tang S, Li B, Chen W. Pgc1-alpha in diabetic kidney disease: unraveling renoprotection and molecular mechanisms. Mol Biol Rep. 2024; 51(1): 304.

[26] Das P, Chakrabarti O. Isgylation of drp1 closely balances other post-translational modifications to mediate mitochondrial fission. Cell Death Dis. 2024; 15(3): 184.

[27] Bredow C, Thery F, Wirth EK, et al. Isg15 blocks cardiac glycolysis and ensures sufficient mitochondrial energy production during coxsackievirus b3 infection. Cardiovasc Res. 2024; 120(6): 644-657.

[28] Huang Y, Zhou JH, Zhang H, et al. Brown adipose trx2 deficiency activates mtdna-nlrp3 to impair thermogenesis and protect against diet-induced insulin resistance. J Clin Invest. 2022; 132(9).

[29] Li J, Tan J, Wang T, et al. Cgas-isg15-rage axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer. Exp Hematol Oncol. 2024; 13(1): 63.

[30] Wang Y, Xu G, Wen J, et al. Flavonoid extracted from epimedium attenuate cgas-sting-mediated diseases by targeting the formation of functional sting signalosome. Immunology. 2024; 172(2): 295-312.

[31] Zhao J, Xu G, Hou X, et al. Schisandrin c enhances cgas-sting pathway activation and inhibits hbv replication. J Ethnopharmacol. 2023; 311: 116427.

[32] Lenschow DJ, Giannakopoulos NV, Gunn LJ, et al. Identification of interferon-stimulated gene 15 as an antiviral molecule during sindbis virus infection in vivo. J Virol. 2005; 79(22): 13974-13983.

[33] D'Cunha J, Knight EJ, Haas AL, Truitt RL, Borden EC. Immunoregulatory properties of isg15, an interferon-induced cytokine. Proc Natl Acad Sci U S A. 1996; 93(1): 211-215.

[34] Sharma K, Zhang G, Hansen J, et al. Endogenous adenine mediates kidney injury in diabetic models and predicts diabetic kidney disease in patients. J Clin Invest. 2023; 133(20).

[35] Li L, Xiang T, Guo J, et al. Inhibition of acss2-mediated histone crotonylation alleviates kidney fibrosis viail-1beta-dependent macrophage activation and tubular cell senescence. Nat Commun. 2024; 15(1): 3200.

[36] Yuan N, Diao J, Dong J, et al. Targeting rock1 in diabetic kidney disease: unraveling mesangial fibrosis mechanisms and introducing myricetin as a novel antagonist. Biomed Pharmacother. 2024; 171: 116208.

[37] Zheng C, Huang L, Luo W, et al. Inhibition of stat3 in tubular epithelial cells prevents kidney fibrosis and nephropathy in stz-induced diabetic mice. Cell Death Dis. 2019; 10(11): 848.

[38] Han HG, Moon HW, Jeon YJ. Isg15 in cancer: beyond ubiquitin-like protein. Cancer Lett. 2018; 438: 52-62.

[39] Rroji M, Spasovski G. Transforming diabetes care: the molecular pathways through which glp1-ras impact the kidneys in diabetic kidney disease. Biomedicines. 2024; 12(3).

[40] Sanz AB, Sanchez-Nino MD, Ramos AM, Ortiz A. Regulated cell death pathways in kidney disease. Nat Rev Nephrol. 2023; 19(5): 281-299.

[41] Song Y, Guo F, Zhao Y, et al. Novel lncrna-prader willi/angelman region rna, snrpn neighbour (pwarsn) aggravates tubular epithelial cell pyroptosis by regulating txnip via dual way in diabetic kidney disease. Cell Prolif. 2023; 56(2): e13349.

[42] Zhang K, Li M, Yin K, et al. Hyperoside mediates protection from diabetes kidney disease by regulating ros-erk signaling pathway and pyroptosis. Phytother Res. 2023; 37(12): 5871-5882.

[43] Toldo S, Abbate A. The role of the nlrp3 inflammasome and pyroptosis in cardiovascular diseases. Nat Rev Cardiol. 2024; 21(4): 219-237.

[44] de Carvalho RM, Szabo G. Role of the inflammasome in liver disease. Annu Rev Pathol. 2022; 17: 345-365.

[45] Liu Y, Lei H, Zhang W, et al. Pyroptosis in renal inflammation and fibrosis: current knowledge and clinical significance. Cell Death Dis. 2023; 14(7): 472.

[46] Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol. 2018; 14(5): 291-312.

[47] Chen C, Xu P. Cellular functions of cgas-sting signaling. Trends Cell Biol. 2023; 33(8): 630-648.

[48] Liu Z, Wang D, Zhang J, et al. Cgas-sting signaling in the tumor microenvironment. Cancer Lett. 2023; 577: 216409.

[49] Lu Q, Hu X, Hou Q, et al. Rheb1 deficiency elicits mitochondrial dysfunction and accelerates podocyte senescence through promoting atp5f1c acetylation. Cell Signal. 2024; 124: 111451.

[50] Zeng Y, Guo M, Wu Q, et al. Gut microbiota-derived indole-3-propionic acid alleviates diabetic kidney disease through its mitochondrial protective effect via reducing ubiquitination mediated-degradation of sirt1. J Adv Res. 2024.

[51] Luo Y, Zhang L, Su N, Liu L, Zhao T. Yme1l-mediated mitophagy protects renal tubular cells against cellular senescence under diabetic conditions. Biol Res. 2024; 57(1): 10.

[52] Huang J, Yang F, Liu Y, Wang Y. N6-methyladenosine rna methylation in diabetic kidney disease. Biomed Pharmacother. 2024; 171: 116185.

[53] Lizotte F, Rousseau M, Denhez B, et al. Deletion of protein tyrosine phosphatase shp-1 restores sumoylation of podocin and reverses the progression of diabetic kidney disease. Kidney Int. 2023; 104(4): 787-802.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.